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Sarafotoxins (SRTa, SRTb and SRTc) as well as endothelin-1 (ET-l) produced vasoconstrictions in rat thoracic aorta, rat isolated perfused mesente- 
ry and pithed rat in various of extents. The potency was ET-l > SRTb > SRTa > SRTc at lower doses, but SRTb > ET-I > SRTa > SRTc 
at higher doses. [Nitrophenylsulfenylated Tt@r]SRTb and SRTb(l-19) caused no vasoconstriction. Either the reduction and carboxymethylation 
of Cys residues, the destruction of the intramolecular loop or the production of the non-natural disulfide bond, eliminated the constrictor activity. 
These results indicate that TrpZr and the intramolecular loop structure are essential, and Lys9 and Tyr*” may play some important roles for the 
vasoconstrictor activity of these peptides. 
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1. INTRODUCTION 
Sarafotoxin S6a (SRTa), sarafotoxin S6b (SRTb) and 
sarafotoxin S6c (SRTc) are new cardiotoxic isotoxins 
isolated from the venom of the burrowing asp Atruc- 
taspis engaddensis [ 1,2]. It has been reported that SRTb 
provides powerful coronary vasoconstriction, positive 
inotropic effect and severe atrioventricular block in 
mice, rats and humans [3]. Sarafotoxins consist of 21 
amino acid residues with two sets of intrachain disulfide 
linkages [4] and show a high sequence homology with 
endothelin-1 (ET-l) [5], a potent vasoconstrictor pep- 
tide obtained from porcine aortic endothelial cells [6]. 
In the present study, the vasoconstrictor activity of 
sarafotoxins was studied using three animal models in 
order to characterize the structural moiety of sarafotox- 
ins which is essential for vasoconstrictor activity in 
comparison with a variety of synthetic SRTb analogs. 
solution of the following composition (mM):NaCl 119.0, KC1 4.7, 
CaClr 2.5, KHzP04 1.2, MgS04 1.0, NaHCOr 25.0, dextrose 11.1, 
maintained at 37°C and continuously bubbled with a mixture of 95% 
02 and 5% CO2. Contractile response was measured isometrically us- 
ing a force displacement transducer (AE875, AME). The resting ten- 
sion was adjusted to 1.0 g. After 2 h equilibration, contractile 
response to 40 mM KC1 was repeated at intervals of 30 min until a 
steady response was obtained. The concentration-response r lation- 
ships for sarafotoxins and ET-1 were determined by means of 
cumulative administrations. The response to these peptides was ex- 
pressed as a percent of the contractile response due to 40 mM KC1 
which was taken as 100%. 
2.2. Rat isolated perfused mesentery 
2. MATERIALS AND METHODS 
2.1. Rat aortic ring 
Male Sprague-Dawley rats (Charles River, Japan, 300-350 g) were 
sacrificed by cervical dislocation and the thoracic aorta was excised 
and cleaned of the surrounding tissues. The endothelium was 
mechanically removed by rolling a small forceps on the luminal sur- 
face of the aortic rings. Ring preparations (approximately 4 mm in 
length) were mounted in 10 ml organ bath filled with Krebs-Henseleit 
Mesenteric arteries of male Sprague-Dawley rats (Charles River, 
Japan, 300-350 g) were isolated and perfused as described by 
McGregor [7]. The rats were anesthetized with sodium pentobarbital 
(35 mg/kg i.p.) and treated with heparin (1300 U/kg i.v.). The 
superior mesenteric artery was cannulated at its origin, flushed with 
I5 ml of Krebs-Ringer solution, and isolated by cutting along the in- 
testinal border of the mesentery. Mesenteric vasculature preparations 
were perfused with Krebs-Ringer solution using a Perista pump 
(SJ-1215, Atto) at a rate of 5 ml/min. The Krebs-Ringer solution, 
maintained at 37°C and continuously bubbled with a mixture of 95% 
02 and 5% CO2, had the following composition (mM): NaCl 130.0, 
KC1 4.8, CaC12 .2, KHzP04 1.2, MgS04 1.2, NaHCOs 25.0, dextrose 
5.5. The isolated mesenteric artery was initially perfused for a 30 min 
conditioning period. The perfusion pressure was measured by means 
of a pressure transducer (MPU-0.5, Tohyo and 1258, NEC San-ei). 
The peptides were injected into the arterial cannula using a microsyr- 
inge (Kloehn) in a volume of 3-30 ~1. 
2.3. Pressor activity in pithed rats 
Correspondence address: K. Tasaka, Department of Pharmacology, 
Faculty of Pharmaceutical Sciences, Okayama University, Tsushima- 
naka l-1-1, Okayama 700, Japan 
Male Sprague-Dawley rats (Charles River, Japan, 250-350 g) were 
anesthetized with diethyl ether and pretreated with atropine sulfate (1 
mg/kg i.p.) The vagi were cut, and both the jugular veins and the left 
common carotid artery were occluded. After the trachea was can- 
nulated, the rats were pithed by passing a steel rod (1.5 mm in 
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diameter) through the orbit and down into the spinal canal via the 
foramen magnum. Immediately after pithing, the tracheal cannula 
was connected to a respirator @N-480-7, Shinano) and the rats were 
ventilated artificially. Systemic arterial blood pressure was recorded 
from the right common carotid artery using a pressure transducer 
(MPU-0.5, Tohyo and 1258, NEC San-ei). Heart rate was measured 
by a pressure pulse-triggered cardiotachometer (1321, NEC San-ei). 
The caudal vein was cannulated for the administration of drug in a 
fixed volume of 1 ml/kg. The preparation was rested to reach the 
stabilized blood presure for at least 30 min before drug administra- 
tion, Under these conditions, mean blood pressure was 53.8 rt 0.9 
mmHg (n = 49, mean f SE). 
2.4. Drugs 
SRTa, SRTb and SRTc were isolated and purified from the venom 
of the snake Atractasph engaddensis, as described previously ]4]. The 
venom was provided by Dr. E. Kochva (Tel Aviv University). SRTb 
(I-19) and SRTb (i-18) were prepared by the digestion of SRTb with 
carbox~tidase Y (Oriental Yeast Co.), and [Des S-9]SRTb and 
SRTb(S-9) were prepared by the digestion with lysyl endopeptidase 
(Wako Pure Chemical). [Homoserine6]SRTb ([Hse6]SRTb) was con- 
verted from SRTb with cyanogen bromide treatment using 100 mol 
eq. of BrCN in 70% formic acid at 37°C for 6 h. At above conditions, 
the methionine residue at position 6 of SRTb was converted into a 
homoserine residue but the resulting Hse’-Thr7 bond was not cleaved. 
These peptides were purified by means of reverse-phase HPLC using 
a Pep RPC HRSIS column (Pharmacia Fine Chemicals). 
[Cys’ - “,Cys’- “]SRTb and SRTb(8-21) were synthesized by the 
solid-phase method. The reduced and carboxymethylated (RCM), 
iodinated (Iod) or nitrophenylsulfenylated (NPS) products of SRTb 
were separated by reverse-phase HPLC. ET-1 was obtained from 
Peptide Institute (Osaka). Peptides were dissolved to lo-’ M in PBS 
containing 0. I % bovine serum albumin (Sigma) and stored in aliquots 
at - 20°C until use. The peptide stock solution was serially diluted 
with the same buffer immediately before use. 
2.5. Statistical analysis 
Data were expressed as means + SE. Statistical analysis of data 
was conducted by Student’s t-test. P<O.O5 indicated statistical 
significance. 
3. RESULTS 
In endothelium denuded rat aorta, SRTb and ET-1 
caused slowly developing and concentration-dependent 
v~oconstrictions, with the EC50 values of 4.4 x 10e9 
M and 1.3 x 10m9 M, respectively (fig.1). The 
threshold concentration of SRTb was 3 times larger 
than that of ET-l, while the response induced by SRTb 
at lo-’ M (150.7 +: 5.3070, n = 4) was greater than 
that of ET-1 (129.7 + 7.5%, n = 5). The vaso- 
constrictor activity of SRTa was less than that of SRTb 
by approximately one order of magnitude. SRTc caused 
no vasoconstriction even at concentrations of 10 - ’ M. 
In isolated perfused mesentery of rat, the mean per- 
fusion pressure was 13.7 f 0.3 mmHg (n = 60). In- 
traarterial injections of SRTb and ET-1 caused dose- 
dependent increase in perfusion pressure at doses rang 
ing from 30 to 300 pmol and from 10 to 300 pmol, 
respectively (fig.2). The vasoconstrictor activity of 
SRTb was less remarkable than that of ET-1 at doses 
lower than 100 pmol, while at a dose of 300 pmol the ac- 
tivity of SRTb was greater than that of ET-l. The time 
required for the recovery of perfusion pressure to base- 
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Fig. 1. Cumulative concentration-response curves for SRTa(o)-, 
SRTb( A)-, SRTcf=)- and ET-l(e)-induced contractions of denuded 
rat aortic rings. Contraction is expressed as the percentage of 40 mM 
KCl-induced contraction. Each point represents mean f SE 
(n = 4-5). 
lines after a bolus injection of 300 pmol SRTb was 
14.9 k 1.7 min (n = 3) which is shorter than that of 
ET-l (2 30 min, n = 3). The threshold v~~onstri~tor 
dose of SRTa was 3 times larger than that of SRTb. At 
a dose of 300 pmol, the rise in perfusion pressue due to 
SRTa was 8 times smaller than that of SRTb. SRTc ex- 
hibited a feeble vasoconstriction producing a rise in per- 
fusion pressure of 1.0 Z!Z 0.2 mmHg (n = 3) even at a 
oose (pmol i.8.) 
Fig.2. Dose-response curves for the vasoconstrictor effects of 
SRTa(o), SRTb( A), SRTc(#. ET-l(*), fod-SRTb(0) and 
[Hse6]SR~(A) in rat isofated perfused mesenteries. Each point 
represents mean it SE (n = 3-5). 
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Fig.3. Structure-activity relationships in vasoconstrictor effects of 
sarafotoxins in rat isolated perfused mesenteries. Vasoconstrictor ac- 
tivity at a dose of 300 pmol i.a. is expressed as the percentage of 
SRTb-induced increase in perfusion pressure. C, cystine; D, aspartic 
acid; E, glutamic acid; F, phenylalanine; H, histidine; Hse, 
homoserine; I, isoleucine; K, lysine; L, leucine; M, methionine; N, 
asparagine; Q, glutamine; S, serine; T, threonine; V, valine; W, tryp- 
tophan; Y, tyrosine. 
dose of 300 pmol. The vasoconstrictor activity 
[iodinated Tyr13]SRTb (Iod-SRTb) was equipotent 
that of SRTb. On a molar basis, the potency 
[Hse6]SRTb was 3 times less effective than that _ ._ ^ __ 
of 
to 
of 
of 
SRTb. In contrast, none of [Cys’ - “,Cys’ - “]SRTb, 
reduced and carboxymethylated SRTb (RCM-SRTb), 
[nitrophenylsulfenylated Trp”]SRTb (NPS-SRTb), 
[Des 5-9]SRTb, SRTb(5-9), SRTb(l-19), SRTb(l-18) 
and SRTb(8-21) induced any rise in perfusion pressure 
up to a dose of 300 pmol (fig.3). 
In pithed hypotensive rat, either of SRTa, SRTb, 
SRTc and ET-l produced a dose-dependent and long- 
lasting increase in blood pressure (fig.4). The duration 
of the hypertensive response to 1 nmol/kg of SRTb 
1 mh 
Fig.4. Typical recordings for pressor responses of pithed hypotensive 
rats to i.v. bolus injections of sarafotoxins and ET-l. 
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Fig.5. Dose-response curves for the hypertensive ffects of SRTa(o), 
SRTb(A), SRTc(m) and ET-l(*) in pithed rats. Each point represents 
mean + SE (n = 4-5). 
(37.7 + 1.9 min, n = 5) was significantly shorter than 
that of ET-l (48.5 + 2.5 min, n = 4), while the 
magnitude of the sustained rise was more prominent. 
The hypertensive ffect of SRTa (1 nmol/kg i.v.) was 
similar to that of SRTb, while its potency was less than 
that of SRTb. The hypertensive response due to SRTc 
was appreciably different from those of other peptides. 
The increase in blood pressure induced by SRTc 1 
nmol/kg reached the highest level about 25 min after 
the bolus injection and declined very slowly thereafter. 
On a molar basis, the increase in blood pressure elicited 
by SRTc was least in these peptides. On the other hand, 
SRTa, SRTb, SRTc and ET-l at a dose of 1 nmol/kg 
caused no remarkable changes in heart rate of pithed 
rats. Fig. 5 shows the dose-response curves for the ef- 
fects of sarafotoxins and ET-l measured at the peak of 
the sustained rise in pithed rat. At doses ranging from 
0.1 to 1.0 nmol/kg i.v., the rank order of the peak 
pressor activity was SRTb 2 ET-l > SRTa 2 SRTc. 
4. DISCUSSION 
In the present study it was demonstrated that all three 
isopeptides of sarafotoxin and ET-l showed various 
vasoconstrictor activities in the experiments carried out 
using rat thoracic aorta, rat isolated perfused mesentery 
and pithed rat, and that the characteristics of the phar- 
macological activities were quantitatively different 
among these isopeptides. The vasoconstrictor effect of 
ET-I was in accordance with the results reported by 
Godfraind et al. [8], Warner et al. [9,10] and Walder et 
al. [9,1 I]. In rat thoracic aorta, the contractile activity 
was ET-l > SRTb > SRTa > SRTc at lower concen- 
trations, but SRTb > ET-l > SRTa > SRTc at higher 
concentrations. The rank order of potency in rat 
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thoracic aorta closely paralleled the order in rat isolated 
perfused mesentery and was similar to the order of peak 
pressor effect in pithed rat. Yanagisawa et al. have 
reported that the cluster of alternating charges, 
A~p~-Lys~-Glu’~, is highly conserved among the en- 
dothelin family, suggesting the importance of these 
regions for biological activity [ 121. The low reactive 
potency of SRTc indicates that the lysine residue at 
position 9 (replaced by glutamic acid in SRTc) is prac- 
tically important for the vasoconstrictor activities of 
sarafotoxins and endothelin family. Furthermore, 
SRTb was more potent than SRTa, indicating that the 
tyrosine residue at position 13 (replaced by asparagine 
in SRTal) is aiso contributable to vasoconstrictive ac- 
tions of endothelin family and SRTb. NPS-SRTb with 
nitrophenylsulfenylated Trp”, SRTb(l-19) and 
SRTb(l-18) caused no vasoconstriction in the 
mesentery of rat. The destruction of two sets of in- 
trachain disulfide linkages by reduction and carbox- 
ymethylation (RCM-SRTb), the deformation of the in- 
tr~olecular loop’ ([Des 5-9]SRTb) or the production 
of the two non-natural disulfide bonds at positions of 
Cys(l-11) and Cys(J-15) (ICys’ - 11,Cys3 - 15]SRTb) all 
caused disappearance of the constrictor activity. These 
results are compatible with the structure-activity rela- 
tionships determined in ET-1 and its analogs [ 131. This 
may suggest hat the C-terminal Trp2’ and the proper 
intramoiecular loop structure are essential for the ex- 
pression of the constrictor activity. 
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